作者: Nandini Dey , Yuliang Sun , Brian Leyland-Jones , Pradip De
关键词:
摘要: Patient derived xenograft (PDX) is defined as a growth of patients’ tumor in the setting. The evolution cancer model animal has century old history. most single reason that exerted pressure on traditional to evolve PDX models have not delivered expected and predicted clinical success. In spite well above 50 drugs developed approved for oncology over last several decades, there remains nirking paucity success reminder this war riding far from won. backbreaking attempt analyze failure, limitation “model” system appeared be rational cause shortcoming. It was more failure test drug rather than make stunted our collective research. product age-old its fitness currently tested virtually all organ-type solid tumors. This review will present appraise context evolution, future promise, limitations specifically, current content different tumors including breast, lung, colorectal, prostrate, GBM, pancreatic, hepatocellular carcinoma melanoma.